Market Overview
Global Foot and Mouth Disease (FMD) Vaccines for Pig market was valued at USD 203 million in 2024 and is projected to reach USD 416 million by 2031, exhibiting a CAGR of 11.0% during the forecast period.
Foot and Mouth Disease (FMD) vaccines for pigs are designed to provide active acquired immunity against this highly contagious viral disease, which primarily affects cloven-hoofed livestock such as pigs, cattle, sheep, and goats. These vaccines work by stimulating the animal's immune system to recognize and combat the FMD virus, preventing severe outbreaks that can devastate herds.
Common types include inactivated vaccines and synthetic peptide vaccines, each offering varying levels of protection and ease of administration.
416 million by 2031 USD 203 million in 2024
of 11.0%
Inactivated Vaccine Segment Dominates the Market Due to its Proven Efficacy and Established
Use in Large-Scale Pig Vaccination Programs
The market is segmented based on type into:
Inactivated Vaccine
Synthetic Peptide Vaccine
Inactivated vaccines remain the cornerstone of FMD prevention in pigs, offering reliable protection against clinical disease manifestations and viral transmission.
By Application
Conventional Vaccines Segment Leads Due to Routine Implementation in Preventive Health Strategies for Commercial Pig Farming
The market is segmented based on application into:
Conventional Vaccines Emergency Vaccines
Portable Neuromonitoring Device Market
Conventional vaccines support proactive herd management by providing sustained immunity through scheduled dosing, which is critical for minimizing economic disruptions in pork production. Emergency vaccines, on the other hand, serve as rapid-response tools during active outbreaks, enabling quick containment to limit spread and restore operations swiftly in affected areas.
Our Key Players
Jinyu Group
Cavet Bio
CAHIC
Tecon Group
Shen Lian
BIGVET Biotech
Biogenesis Bago
https://www.24lifesciences.com
